Efficacy and Safety of Intralesional Triamcinolone Acetonide Alone and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Percentage of change in Vancouver Scar Scale score in two treatment groups
研究概览
简要总结
Summary: Keloids and hypertrophic scars are benign fibrous growth, differing mainly by overgrowth beyond the initial defect in keloid whereas hypertrophic scar is confined to initial lesion and tends to regress over the years. Keloids and hypertrophic scars mainly lead to cosmetic disfigurement and functional deformity depending on site of involvement, in addition to symptoms like pain and pruritus, encountered occasionally. These sometimes might lead to psychological impact too. Different treatment options for keloids and hypertrophic scar are silicone gel/ sheets, corticosteroids, cryotherapy, lasers, antineoplastic agents (5-FU, mitomycin-C), surgical excision and immunomodulators (imiquimod) used either as monotherapy or combination therapy. Different studies involving combination of TAC and 5-FU have been done so far which shows better treatment outcome in terms of efficacy and safety. In a recent meta-analysis published in 2017 concluded that combination therapy of 5-FU + TAC offers better outcome than TAC alone, however recommended additional randomized, controlled, large-sample, high quality trial are needed for a more objective analysis of the treatment efficacy and to assess the adverse reaction associated. We are conducting this study the objective to compare the efficacy and safety profile of intralesional triamcinolone acetonide alone and its combination with 5-FU of the treatment of keloids and hypertrophic scars. This study may help in finding out the optimum treatment option in keloid and hypertrophic scar with minimal side effects in our clinical practice.
详细描述
HYPOTHESIS Null hypothesis: There is no difference in the efficacy of intralesional triamcinolone acetonide alone and its combination with 5-flurouracil in the treatment of keloids and hypertrophic scars Alternate hypothesis: Combination of intralesional triamcinolone and 5- fluorouracil is more efficacious than intralesional triamcinolone alone in treatment of keloids and hypertrophic scars
METHODS
Sample size: Sample size:
This study considers a 95% confidence interval, 80% power to estimate sample size. According to the article published in the Clinical and experimental dermatology by Darougegh A et al in 2009 comparing the efficacy of Intralesional Triamcinolone alone versus combined with 5 FU in treatment of keloids, it was found that the patient reported good to excellent (> 50%) 30 | P a g e improvement in TAC alone group was 20% whereas that of the combination of TAC and 5-FU was 55% (22). Now using the sample size estimation formula for 2 proportions based on above study, n = {2p(1-p) (Zβ + Zα/2)2}/ (p1-p2)2 Where n= sample size for each group; p1 = 0.55; p2 = 0.2; p= (p1 +p2)/2; Zα/2=1.96 at 95% CI; Zβ = 0.842 at 80% power; using above formula, n= 30. Adding 10% in calculated value to consider the drop out, the minimum sample size in each group will be 30+3=33; Thus, a total sample size will be 66 The study is double blinded ,both participants and investigator( treatment provider/assessor) are blinded. Total of 66 patients are enrolled into the study , 33 in each groups allocated by block randomization through computer generated block randomization list. Patients with a clinical diagnosis of keloids or hypertrophic scars attending the outpatient department of dermatology at BPKIHS will be enrolled in the study. Written and understood informed consent will be taken prior to the enrollment and treatment. Detailed information of all the patients satisfying inclusion criteria will be recorded in preset pro forma. This will include personal data, past history, medical history, drug history, clinical data like site, size, number, distribution of lesions, complaints related to scar like pain, pruritus, erythema, scar score and cutaneous examination. Patients will be excluded according to the exclusion criteria. Photographs of the lesions will be taken before the first treatment session, in every treatment session and at the completion of treatment at 12th week. Only one lesion (preferably on the trunk or proximal extremity) will be treated per patient.
Study Treatments:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
盲法说明
This study will be double blinded with both the participants (keloid/hypertrophic scar patient fulfilling all the criteria)) and trial investigator (treatment provider) being blinded. The participants will be unaware of the treatment group that they will be allocated. And even the investigator performing the procedure and assessing the scar in each visit will be unaware of the drugs that will be given.
The independent dermatologist, which will have the sealed envelope will open the envelope and instruct the trained nurse to prepare the mixture of drugs as the group written in the envelope and provide it to the blinded investigator after removing the label on the mixture of drug.
入排标准
- 年龄范围
- 16 Years 至 —(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patient with clinically diagnosed keloid or hypertrophic scar
- •Size of scar 1cm in length or more
- •Informed consent given
排除标准
- •Under treatment of keloids or hypertrophic scar in past 6 months
- •Patient with renal disease
- •Patient with liver disease
- •History of Hypersensitivity to 5-fluorouracil or triamcinolone acetonide
- •Immunosuppressed conditions: HIV, Immunosuppressive therapy, Uncontrolled diabetes
- •Pregnant or lactating women or patient planning for pregnancy
- •Open wound in the scar
- •Atrophic scar
- •Patients suffering from chronic infectious conditions like Tuberculosis
- •Patients with low WBC count
研究组 & 干预措施
Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;
Group A: 1 ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline. 5 units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units,covering an area of 0.5X0.5 cm2 of scar. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs( maximum dose=2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
干预措施: 5-Fluorouracil (Drug)
Group B: Intralesional triamcinolone acetonide and 5-fluorouracil (5-FU) combination
Group B: 1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU.
Injection Method: Five units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. (maximum dose 2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks), Post treatment follow up: at 12 weeks.
干预措施: 5-Fluorouracil (Drug)
结局指标
主要结局
Percentage of change in Vancouver Scar Scale score in two treatment groups
时间窗: Starting of treatment to 12 weeks follow up of treatment
Compare the change in Vancouver Scar Scale from baseline to 12 week follow up in each group in percentage
Percentage of change in height of scar pre and post treatment in each groups
时间窗: Starting of treatment to 12 weeks follow up of treatment
Compare the change in height in millimeter of scar pre and post treatment in percentages in each treatment groups
Percentage of reduction in The Patient and Observer Scar Assessment Score) score in two treatment groups
时间窗: Starting of treatment to 12 weeks follow up of treatment
Compare the reduction in The Patient and Observer Scar Assessment Score from baseline to 12 week follow up in each group in percentage
Percentage of good to excellent subjective improvement in two groups combination with 5-flurouracil in the treatment of keloids and hypertrophic scars at 12 weeks follow up
时间窗: Starting of treatment to 12 weeks follow up of treatment
Compare the good to excellent improvement (\>50% subjective improvement) in the scars in two treatment groups in percentage
次要结局
- Percentages of Side effects of treatment groups(Starting of treatment to 12 weeks follow up of treatment)
研究者
Ripala Acharya
Junior resident
B.P. Koirala Institute of Health Sciences
